Thirteen years of intravitreal anti-vascular endothelial growth factor therapy: the promises and burdens of a paradigm shift told from the perspective of the largest retina service in Norway.
Øystein Kalsnes JørstadLeif Arthur SteffensenKetil EriksenRagnheiður BragadóttirMorten Carstens MoePublished in: Acta ophthalmologica (2019)
In 13 years there was an approximately 100-fold increase in the number of yearly intravitreal injections. A majority of patients received long-term treatment. Macular degeneration was the most common diagnosis. Using bevacizumab as first-line treatment, with aflibercept reserved for resistant cases from 2013, eventually resulted in a nearly 1:1 ratio in drug usage.
Keyphrases
- vascular endothelial growth factor
- diabetic retinopathy
- age related macular degeneration
- end stage renal disease
- endothelial cells
- ejection fraction
- chronic kidney disease
- newly diagnosed
- mental health
- healthcare
- optical coherence tomography
- peritoneal dialysis
- prognostic factors
- emergency department
- patient reported outcomes
- cell therapy
- combination therapy
- optic nerve
- metastatic colorectal cancer
- smoking cessation
- cataract surgery